

NCT ID	NCT03867799
Title	iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer
Phase	Phase 2
Date Added	2019-03-08
Location	United Kingdom
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Nivolumab
Tags	MSS/ MMRp
<hr/>	
NCT ID	NCT03865082
Title	Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)
Phase	Phase 2
Date Added	2019-03-06
Location	Arizona, United States California, United States Texas, United States
Prior IO Allowed	No
CRC-directed	No
Status	Active, not recruiting
Drugs	Ipilimumab, Nivolumab, Tilsotolimod, Opdivo, Yervoy
Tags	MSS/ MMRp
<hr/>	
NCT ID	NCT03860272
Title	Fc-Engineered Anti-CTLA-4 Monoclonal Antibody Botensilimab in Advanced Cancer
Phase	Phase 1
Date Added	2019-03-01
Location	Arizona, United States California, United States Colorado, United States Connecticut, United States Florida, United States Massachusetts, United States New York, United States Oregon, United States Texas, United States United Kingdom
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Balstilimab, Botensilimab
Tags	MSI-H/ MMRd, MSS/ MMRp
<hr/>	
NCT ID	NCT03851614
Title	Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors
Phase	Phase 2
Date Added	2019-02-22
Location	Canada
Prior IO Allowed	Yes
CRC-directed	Yes

Status	Active, not recruiting
Drugs	Cediranib, durvalumab, Olaparib
Tags	MSS/ MMRp
NCT ID	NCT03844750
Title	Pembrolizumab After Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and Who Are Undergoing Liver Surgery
Phase	Phase 2
Date Added	2019-02-18
Location	California, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Pembrolizumab, Vactosertib, Keytruda
Tags	MSS/ MMRp
NCT ID	NCT03835949
Title	Study of TJ004309 in Combination With Atezolizumab (Tecentriq(R)) in Patients With Advanced or Metastatic Cancer
Phase	Phase 1
Date Added	2019-02-11
Location	Alabama, United States Arizona, United States California, United States Texas, United States
Prior IO Allowed	No
CRC-directed	No
Status	Active, not recruiting
Drugs	Atezolizumab, TJ004309
Tags	MSS/ MMRp
NCT ID	NCT03832855
Title	Assessing the Immunogenicity of pING-hHER3FL
Phase	Phase 1
Date Added	2019-02-06
Location	North Carolina, United States
Prior IO Allowed	Yes
CRC-directed	No
Status	Recruiting
Drugs	pING-hHER3FL
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03829462
Title	Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients
Phase	Phase 3
Date Added	2019-02-04
Location	France
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Irinotecan, Regorafenib
Tags	MSI-H/ MMRd, MSS/ MMRp

NCT ID	LUMINESCENCE
Title	Ipilimumab, Maraviroc and Nivolumab (LUMINESCENCE)
Phase	Phase 1
Date Added	2019-01-25
Location	
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Ipilimumab, maraviroc, Nivolumab, Celsentri, Opdivo, Selzentry, Yervoy
Tags	MSS/ MMRp

NCT ID	NCT03796884
Title	Linacotide in Treating Patients With Stages 0-3 Colorectal Cancer
Phase	Phase 2
Date Added	2019-01-08
Location	Pennsylvania, United States Washington, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Linacotide
Tags	MSS/ MMRp